Best Life Sciences Companies in Pittsburgh, United States

Peptilogics has developed antibiotics to target Multi-drug resistant bacteria. The company has developed eCAPS technology to produce novel antibiotics for drug-resistant bacteria. It acts by disrupting the bacterial membrane and inactivating it. It has shown effectiveness against the ESKAPE pathogens, both gram-positive and gram-negative, that cause the majority of resistant hospital-acquired infections.

Funding rounds

• Oct 2025Series B$78M
• Jan 2025Grant (prize money)$3.3M
• Aug 2022Grant (prize money)$499.4K
• Sep 2021Grant (prize money)$698.7K

Founders & team

Jonathan SteckbeckFounder | President | CEO

Investors

Presight Capital, Founders Fund, HHS, AMR Action Fund, Narya, Beyond Venture Partners

Tech stack

All In One SeoBugherdCdnjsChart.JsCloudflareCloudflare Bot Management

Noveome is a developer of biologically active molecules for the treatment of Periodontitis and inflammation diseases. It has developed therapies for the regenerative repair of inflamed or damaged tissues. The company's products are clinical applications of a novel secretome that provides a complex solution of molecules secreted from proprietary cells. Secretome solution contains many biologically active molecules, present in physiological concentrations. Secretome (ST266) is Phase 2 for the treatment of periodontitis that is a serious inflammation of the gums that damages the soft tissue and destroys the bone that supports your teeth.

Developer of pediatric cardiac surgical devices. PECA Labs has developed the MASA valve, a synthetic valved conduit for pediatric right ventricular outflow tract reconstruction. Uses ePTFE material and RVOT-specific design to differentiate from existing alternatives. PECA is developing a valved RV-PA shunt for the treatment of hypoplastic left heart syndrome (HLHS). This device is expected to decrease the high mortality and morbidity rates associated with the Norwood Procedure.

Funding rounds

• Nov 2025Series B$2.7M
• Dec 2024Series B$13.9M
• Nov 2022Conventional Debt$618.2K
• Jun 2021Series A$99.2K

Founders & team

Arush KalraCo-Founder/Chief Scientific Officer

Investors

Innovation Works, BlueTree Allied Angels, HHS, Pittsburgh Life Sciences Greenhouse, Carnegie Mellon University, Mountain State Capital

Tech stack

WebflowJqueryGoogle Hosted LibrariesGoogle Font Api

Provider of pharmaceutical products for the treatment of viral infectious diseases. The company's lead drug candidate modulates the body’s immune response to reduce tissue damage caused by an excessive immune reaction. The drug candidate would decrease the tissue damage resulting from the excessive release of pro-inflammatory cytokines, known as the cytokine release syndrome, which is induced by influenza and other viral infections.

Developer of lipid-based therapies for common bladder syndromes. It offers products that target intravesical therapy for the urinary bladder lumen via urethral catheterization. Indications targeted include interstitial cystitis, overactive bladder and superficial bladder cancer. The products consist of liposome formulations of large multilamellar liposomes made from sphingomyelin lipids which bind to sphingomyelin in the bladder wall, forming a lipid barrier. This protective coating promotes healing and prevents further damage to the bladder wall from urinary toxins.

Developer of nanoparticle-based drugs for the treatment of cancer. The company's lead candidate includes DUO-207: Gemcitabine Paclitaxel Nanoparticles for multiple tumour types and can be used in combination with immune checkpoint therapies. Its also developing other drug candidates to treat pancreatic cancer, bile duct cancer and relapsed metastatic disease.

Medical technology product design and development for clinical translation. The company specializes in bringing medical technologies from concept to clinical application. They adhere to stringent FDA design controls and ISO standards, ensuring high-quality and regulatory compliance. Their core competencies lie in product design, development, and blood compatibility testing. They offer services related to medical devices, focusing on the clinical translation aspect. This indicates a business-to-business (B2B) model, providing specialized services to medical technology companies. They are not a software or SaaS company, but a product design and development firm within the medical technology sector.

Funding rounds

• Jan 2025Grant (prize money)$870.5K
• Feb 2017Grant (prize money)$299.8K
• Aug 2016Grant (prize money)$3.3M
• May 2015Grant (prize money)$225K

Founders & team

Philip LitwakFounderMark GartnerFounder

Investors

HHS

Surgical solutions advancing nerve recovery, restoring hope after nerve injury. The company is dedicated to developing innovative surgical solutions to improve healing following nerve damage. They focus on creating transformative implantable technologies to help patients affected by peripheral nerve injury. Committed to making a real impact, the team approaches their work with rigor, evidence, and high standards. They value collective intelligence, transparency, and frank collaboration. The company believes in a future where nerve injury can be resolved with solutions that are simple, affordable, and available to all. Their mission-driven approach aims to provide the next generation of surgical interventions for nerve repair and pain management.

Funding rounds

• Sep 2025Grant (prize money)$1.3M
• Sep 2025Seed$324.8K
• Sep 2024Grant (prize money)$500K
• Jul 2024Seed$335K

Founders & team

Lorenzo SolettiCo-Founder

Investors

Defense.gov, NIH, America’s Seed Fund, HHS, National Science Foundation, McGovern Center

Tech stack

WixReactGoogle CloudPolyfillLodashPriority Hints

Developer of psychedelic-based therapeutics for mental health conditions. The drug candidates include MSD-101 for PTSD, MSD-201 for depression, and others. The company has an Osmanthus platform for the prediction of phenomenological psychedelic effects.

Funding rounds

• Nov 2024Series A$12.7M
• Feb 2022Seed$11.5M
• Sep 2021Seed$125K

Founders & team

Dillan DiNardoCEO

Investors

Y Combinator, Initialized Capital, Metaplanet, Negev Capital, Day One Ventures, Actions Capital

Tech stack

CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGoogle WorkspaceHsts

Developer of medical devices to treat respiratory conditions. The company develops RelianceET a novel endotracheal tube to reduce ventilator-associated events that replace the error-prone inflatable cuff.

Funding rounds

• May 2025Seed$2.2M
• May 2024Grant (prize money)$299.1K

Founders & team

Carl SnydermanCo-Founder & CTO

Investors

HHS

Developer of medical products for treating chronic skin wound conditions. These products focus on restoring skin function and integrity to facilitate healing. The technology addresses underlying biological factors to reduce complications and recurrence associated with non-healing wounds. The development process incorporates research in wound biology to create therapeutic applications for clinical use.

Funding rounds

• Jul 2025Seed$1.6M

Founders & team

Zachary RichertCo-Founder & VP Strategy & PartnershipsDan WillisCo-Founder & CTODerek GonanoCo-Founder

Provider of a solution for isolating and analyzing extracellular vesicles. It focuses on cancer research and clinical management, specializing in the isolation and analysis of extracellular vesicles which carry valuable molecular information about diseases like cancer.

Funding rounds

• Mar 2025Grant (prize money)$1.1M
• Sep 2023Grant (prize money)$306.5K
• Jun 2023Grant (prize money)$400K
• Aug 2019Grant (prize money)$357K

Founders & team

HongZhang HECo-Founder & CEO

Investors

HHS